Tags

Type your tag names separated by a space and hit enter

[COVID-19 from the Perspective of Haematology and Haemostaseology].
Dtsch Med Wochenschr. 2020 Jul; 145(15):1044-1050.DM

Abstract

Infection with SARS-COV-2 leads to a number of pathologies in the hematopoetic system that have significant impact on clinical symptoms and mortality. There are 3 stages of infection: (1) early upper respiratory tract infection with fever and lymphopenia (2) pulmonary phase and (3) hyperinflammatory phase with the clinical signs of organ failure such as ARDS/shock. Hyperinflammation, which is triggered by activation of T cells and monocytes/macrophages, is essential for organ pathologies. Interferon IFN-ɣ, tumor necrosis factor (TNF)-α, IL-10 and interleukin-6 (IL-6) play important roles as mediators of inflammation. In analogy to the cytokine release syndrome (CRS) after CAR-T cell therapy, the therapeutic activity of the IL-6 receptor antibody tocilizumab is investigated in clinical studies.The coagulation system is activated during the inflammatory phase of COVID infection, most likely on the pathophysiological basis of immune thrombosis. Clinically, there is a significantly increased incidence of venous (especially pulmonary artery embolism), but also arterial thromboembolism (TE). In laboratory chemistry, the D-dimer, fibrinogen but also vWF and FVIII are significantly increased. Guidelines for the prophylaxis and therapy of COVID-associated coagulopathy have been developed. Analogous to other viral infections, there are approaches to passive immunization using convalescent plasma. Its administration has shown promising activity in first uncontrolled case series and is currently being examined in clinical studies worldwide for its therapeutic activity.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

ger

PubMed ID

32731277

Citation

Spiekermann, Karsten, et al. "[COVID-19 From the Perspective of Haematology and Haemostaseology]." Deutsche Medizinische Wochenschrift (1946), vol. 145, no. 15, 2020, pp. 1044-1050.
Spiekermann K, Subklewe M, Hildebrandt M, et al. [COVID-19 from the Perspective of Haematology and Haemostaseology]. Dtsch Med Wochenschr. 2020;145(15):1044-1050.
Spiekermann, K., Subklewe, M., Hildebrandt, M., Humpe, A., & von Bergwelt-Baildon, M. (2020). [COVID-19 from the Perspective of Haematology and Haemostaseology]. Deutsche Medizinische Wochenschrift (1946), 145(15), 1044-1050. https://doi.org/10.1055/a-1164-4191
Spiekermann K, et al. [COVID-19 From the Perspective of Haematology and Haemostaseology]. Dtsch Med Wochenschr. 2020;145(15):1044-1050. PubMed PMID: 32731277.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [COVID-19 from the Perspective of Haematology and Haemostaseology]. AU - Spiekermann,Karsten, AU - Subklewe,Marion, AU - Hildebrandt,Martin, AU - Humpe,Andreas, AU - von Bergwelt-Baildon,Michael, Y1 - 2020/07/30/ PY - 2020/7/31/entrez PY - 2020/7/31/pubmed PY - 2020/8/14/medline SP - 1044 EP - 1050 JF - Deutsche medizinische Wochenschrift (1946) JO - Dtsch. Med. Wochenschr. VL - 145 IS - 15 N2 - Infection with SARS-COV-2 leads to a number of pathologies in the hematopoetic system that have significant impact on clinical symptoms and mortality. There are 3 stages of infection: (1) early upper respiratory tract infection with fever and lymphopenia (2) pulmonary phase and (3) hyperinflammatory phase with the clinical signs of organ failure such as ARDS/shock. Hyperinflammation, which is triggered by activation of T cells and monocytes/macrophages, is essential for organ pathologies. Interferon IFN-ɣ, tumor necrosis factor (TNF)-α, IL-10 and interleukin-6 (IL-6) play important roles as mediators of inflammation. In analogy to the cytokine release syndrome (CRS) after CAR-T cell therapy, the therapeutic activity of the IL-6 receptor antibody tocilizumab is investigated in clinical studies.The coagulation system is activated during the inflammatory phase of COVID infection, most likely on the pathophysiological basis of immune thrombosis. Clinically, there is a significantly increased incidence of venous (especially pulmonary artery embolism), but also arterial thromboembolism (TE). In laboratory chemistry, the D-dimer, fibrinogen but also vWF and FVIII are significantly increased. Guidelines for the prophylaxis and therapy of COVID-associated coagulopathy have been developed. Analogous to other viral infections, there are approaches to passive immunization using convalescent plasma. Its administration has shown promising activity in first uncontrolled case series and is currently being examined in clinical studies worldwide for its therapeutic activity. SN - 1439-4413 UR - https://www.unboundmedicine.com/medline/citation/32731277/[COVID-19_from_the_Perspective_of_Haematology_and_Haemostaseology] L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/a-1164-4191 DB - PRIME DP - Unbound Medicine ER -